Journal
TRANSPLANTATION REVIEWS
Volume 26, Issue 4, Pages 233-240Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trre.2012.02.001
Keywords
Efficacy; EC-MPS; Immunosuppression; MMF; Mycophenolic acid; Kidney transplant; GI tolerability
Categories
Ask authors/readers for more resources
Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both short- and long-term outcomes following renal transplantation, but is often associated with gastrointestinal (GI) complications that can lead to dose reduction or discontinuation, potentially jeopardizing patient outcomes. Enteric-coated mycophenolate sodium (EC-MPS) delivers equivalent MPA exposure to MMF and offers the potential to reduce GI burden (while maintaining patient safety). Here we review the efficacy of EC-MPS compared with MMF in renal transplant patients in terms of biopsy-proven acute rejection and graft loss, and examine the use of EC-MPS in newer regimens such as intensified dosing and calcineurin inhibitor minimization. (C) 2012 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available